Literature DB >> 22446640

Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine.

Manki Song1, Huynh A Hong, Jen-Min Huang, Claire Colenutt, Dinh Duy Khang, Thi Van Anh Nguyen, Sung-Moo Park, Byoung-Shik Shim, Ho Hyun Song, In Su Cheon, Ji Eun Jang, Jung-ah Choi, Young Ki Choi, Konrad Stadler, Simon M Cutting.   

Abstract

Heat killed spores of the Gram-positive bacterium Bacillus subtilis have been evaluated as a vaccine delivery system with mucosal adjuvant properties for influenza. Killed spores were able to bind H5N1 virions (NIBRG-14; clade 1) and, when intra-nasally administered to mice, resulting immune responses, both humoral and cell mediated, were enhanced compared to immunization with the virion alone. Levels of both systemic IgG and mucosal sIgA specific to the virion were elevated. Levels of IgG2a (a Th(1) antibody type) were strongly enhanced when the virion was co-administered with killed spores. Cytokine induction in stimulated splenocytes was also apparent indicating balanced T(h)1 and T(h)2 responses. Evidence of cross-neutralization of clade 2.2 viruses was shown. In a challenge experiment mice dosed two times with spores adsorbed with just 20 ng HA (hemagglutinin) of inactivated NIBRG-14 were fully protected against challenge with 20 LD(50) of H5N2 virus. Interestingly, partial protection (60%) was observed in animals dosed only with killed spores. Mice dosed only with killed spores were shown to be fully protected against H5N2 (5 LD(50)) infection indicating that innate immunity and its stimulation by spores may play an important role in protection. Supporting this killed spores were (i) shown to stimulate TLR-mediated expression of NF-κB, and (ii) able to recruit NK cells into lungs and induce maturation of DCs. This work demonstrates the potential and underlying mechanism for the use of bacterial spores as an adjuvant for H5N1 vaccination.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446640     DOI: 10.1016/j.vaccine.2012.03.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

Review 2.  Importance of the gastrointestinal life cycle of Bacillus for probiotic functionality.

Authors:  M Bernardeau; M J Lehtinen; S D Forssten; P Nurminen
Journal:  J Food Sci Technol       Date:  2017-05-23       Impact factor: 2.701

Review 3.  Applications of Bacillus subtilis Spores in Biotechnology and Advanced Materials.

Authors:  Xiaopei Zhang; Amal Al-Dossary; Myer Hussain; Peter Setlow; Jiahe Li
Journal:  Appl Environ Microbiol       Date:  2020-08-18       Impact factor: 4.792

4.  Impact of orientation and flexibility of peptide linkers on T. maritima lipase Tm1350 displayed on Bacillus subtilis spores surface using CotB as fusion partner.

Authors:  Jawad Ullah; Huayou Chen; Ake Vastermark; Jinru Jia; Bangguo Wu; Zhong Ni; Yilin Le; Hongcheng Wang
Journal:  World J Microbiol Biotechnol       Date:  2017-08-18       Impact factor: 3.312

5.  Bacillus subtilis strain engineered for treatment of soil-transmitted helminth diseases.

Authors:  Yan Hu; Melanie M Miller; Alan I Derman; Brian L Ellis; Rose Gomes Monnerat; Joe Pogliano; Raffi V Aroian
Journal:  Appl Environ Microbiol       Date:  2013-07-08       Impact factor: 4.792

6.  Anti-influenza Activity of a Bacillus subtilis Probiotic Strain.

Authors:  Darya Starosila; Svetlana Rybalko; Ludmila Varbanetz; Naila Ivanskaya; Iryna Sorokulova
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based mycobacterium tuberculosis-based vaccines: partial requirement for interleukin-17a for induction of protective immunity.

Authors:  Sandra C Esparza-Gonzalez; Amber R Troy; Angelo A Izzo
Journal:  Clin Vaccine Immunol       Date:  2014-01-29

Review 8.  Mucosal vaccine delivery by non-recombinant spores of Bacillus subtilis.

Authors:  Ezio Ricca; Loredana Baccigalupi; Giuseppina Cangiano; Maurilio De Felice; Rachele Isticato
Journal:  Microb Cell Fact       Date:  2014-08-12       Impact factor: 5.328

9.  Mucosal adjuvant activity of IL-2 presenting spores of bacillus subtilis in a murine model of Helicobacter pylori vaccination.

Authors:  Krzysztof Hinc; Małgorzata Stasiłojć; Iwona Piątek; Grażyna Peszyńska-Sularz; Rachele Isticato; Ezio Ricca; Michał Obuchowski; Adam Iwanicki
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action.

Authors:  Renata Damásio de Souza; Milene Tavares Batista; Wilson Barros Luiz; Rafael Ciro Marques Cavalcante; Jaime Henrique Amorim; Raíza Sales Pereira Bizerra; Eduardo Gimenes Martins; Luís Carlos de Souza Ferreira
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.